Tybee Spring Shorebird Festival
Through engaging panel discussions and a family-friendly festival on Saturday, February 22, 2025, attendees will learn how to play a critical role in shorebird conservation andmake a difference in their communities.
The incredible migrations of shorebirds—some covering thousands of miles—connectecosystems across continents and play a key role in maintaining ecological balance. Recentstudies have revealed alarming declines in shorebird populations, with over half of NorthAmerican species experiencing a 50% reduction since 1980.
Manomet Conservation Sciences has worked with partners to advance science-driven solutionsfor conserving shorebirds and their habitats. For example, the U.S. population of the AmericanOystercatcher has rebounded, and the Piping Plover shows promising trends. Manomet has ledthe Oystercatcher Recovery Working Group for over a decade, exceeding its original goal of a30% population increase by achieving a 45% rebound, demonstrating the impact of focusedconservation work.
By protecting shorebirds and their habitats, we also safeguard biodiversity, ensure the health ofcoastal communities, and support economic benefits like ecotourism.
Festival Schedule:Thursday, February 20 | 6:30 p.m. – 8:00 p.m.Shorebird Biologist Panel DiscussionHear from renowned experts in shorebird ecology and conservation during this engaging paneldiscussion. Speakers include:● Abby Sterling, PhD, Director, Georgia Bight Shorebird Conservation Effort, ManometConservation Sciences● Allie Hayser, Georgia Bight Shorebird Conservation Specialist at ManometConservation Sciences● Biologists from the Georgia Department of Natural Resources
Panelists will share insights about shorebird ecology, their experiences in the field, and thepressing challenges facing these remarkable birds along Georgia's coast. A Q&A session willallow attendees to engage directly with the experts.
Friday, February 21 | Noon – 2:00 p.m.Shorebird Training and Bird WalkJoin Abby Sterling and Allie Hayser for an immersive bird walk and citizen science trainingsession. Learn to identify local beach birds and contribute to ongoing conservation efforts bycollecting data for the Georgia Coastal Bird Ambassadors program. This hands-on experience isperfect for those eager to help protect shorebirds and their habitats while connecting withnature.
Birds and Brew Happy Hour @ Back River Brewery | 3:00 p.m. – 5:00 p.m.Meet other birders, check out resources, and chat about shorebirds with a beer and a bite atTybee Island's premier brewery. 401 1st St., Tybee Island
Saturday, February 22 | 11:00 a.m. – 3:00 p.m.
Tybee's First Annual Spring Shorebird FestivalMeet the biologists, students, and community partners that work together on Georgia's coast toprotect these amazing birds. There will be crafts, music, food, partner tables, games, andactivities for all ages
All events take place (except for Friday happy hour) at:Tybee Island Marine Science Center37 Meddin DriveTybee Island, Georgia 31328When:February 20-22, 2025Cost: FREE
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
3 days ago
- Newsweek
These Popular Mushroom Kits Might Be Causing Environmental Harm
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Bright yellow golden oyster mushrooms, prized for their nutty flavor and easy cultivation, have surged in popularity thanks to at-home growing kits. But new research warns that these kits may be unleashing an invasive species into North American forests. A study conducted by researchers in Wisconsin found that trees colonized by golden oyster mushrooms hosted about half as many native fungal species as those without them. DNA analysis from elm tree samples showed that the presence of this invasive fungus, Pleurotus citrinopileatus, reduced both the diversity and composition of native fungi. Stock image of mushrooms. Stock image of mushrooms. Photo by chengyuzheng / Getty Images Aishwarya Veerabahu, a co-author of the study and Ph.D. candidate at the University of Wisconsin-Madison, wrote in The Conversation that the invasive species had displaced fungi such as the mossy maze polypore and the elm oyster. According to Veerabahu, when native species are pushed out, researchers lose the opportunity to study their potential benefits. "I think [mushroom growers] very likely could introduce other types of invasive mushrooms," Veerabahu told Newsweek in an email. "I have my eye on the other non-native species of oyster mushrooms, but in truth it can be any." 'A simple but vital joy' Fungi serve as natural recyclers, breaking down dead wood and plant material and converting it into nutrients that enrich the soil. They also support climate regulation by storing carbon and helping other plants absorb water and nutrients. Disruption to these fungal communities could weaken forest ecosystems already strained by habitat loss and climate change. Veerabahu added that "the invasion of golden oysters risks erasing a simple, but vital, joy of seeing different, colorful, incredible fungi in the forest". "Every winter after the snow melts, fungi growing on dead wood are often the first ones to pop up, and I so love to see them again," she told Newsweek. "Golden oysters might make that experience non-existent. "Fungal biodiversity deserves to exist, period. Moving non-native fungi around the world puts fungal biodiversity at risk, along with everything they have to offer us: vital ecosystem processes, therapeutic medicines, and a deeper understanding of the natural world." What To Know The golden oyster mushroom, native to eastern Asia, was introduced to North America in the early 2000s and gained popularity through home-growing kits and cultivation on outdoor logs. While most cultivated mushrooms remain harmless, golden oysters have spread rapidly since escaping cultivation and are now reported in 25 U.S. states and parts of Canada. "As far as we know, this is the first cultivated species that has escaped," Veerabahu told Newsweek. "So even if a few people had an inkling, most people didn't know this could happen, and it's certainly not anyone's fault." What People Are Saying Veerabahu urged caution in The Conversation: "I recommend that people consider refraining from using golden oyster mushroom grow kits to prevent any new introductions. "For people who make a living selling these mushrooms, consider adding a note that this species is invasive and should be cultivated indoors and not composted." What's Next Veerabahu told Newsweek she plans to continue studying golden oyster mushrooms. Specifically, Veerabahu plans to examine whether the mushrooms have evolved to be genetically distinct from native populations. She also plans to examine the perspectives and priorities of stakeholders in golden oyster mushrooms and how they can be managed going forward.
Business Upturn
3 days ago
- Business Upturn
Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP)
Doptelet Sprinkle (avatrombopag) was approved as an effective formulation for children one year to less than six years. The primary endpoint was met in 27.8% of patients, confirming the efficacy in children and adolescents with persistent or chronic ITP WALTHAM, Mass., July 25, 2025 (GLOBE NEWSWIRE) — Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the U.S. Food and Drug Administration (FDA) approved Doptelet® (avatrombopag) for the treatment of thrombocytopenia in pediatric patients one year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a prior therapy. 1 The approval also includes a new formulation, Doptelet Sprinkle (avatrombopag) oral granules, for use in children ages one to less than six years. 1 'Doptelet represents a significant advancement in the treatment of children and adolescents with persistent or chronic ITP,' said Rachael Grace, MD, MMSc, Pediatric Hematologist and Director, Hematology Clinical Research at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, and lead investigator of the AVA-PED-301 study. 'This therapy offers simple, flexible administration because it is oral, available as a tablet and now as a new pediatric sprinkle formulation and has no food restrictions. The approval of Doptelet for pediatric ITP offers families a new treatment option that can help address challenges in managing ITP in pediatric patients.' Doptelet Sprinkle is the approved dosage form for patients aged one to less than six years, while Doptelet tablet is the approved dosage form for patients aged six and up. 1 The pediatric approval is based on results from AVA-PED-301, a global, randomized, phase 3 study evaluating the efficacy, safety, and pharmacokinetics of Doptelet in the treatment of pediatric subjects with ITP. The study showed that 27.8% of Doptelet patients achieved the primary endpoint of durable platelet response* versus 0% of placebo patients in the absence of rescue medication (p=0.0077, 95% CI 15.8-39.7). Also, 81.5% of Doptelet patients achieved the alternative primary endpoint of platelet response** versus no patients in the placebo group (p=<0.0001, 95% CI 71.1-91.8). At Day 8, 55.6% of Doptelet patients (95% CI: 41.4%, 69.1%) had a platelet count ≥50×10^9/L in the absence of rescue therapy (p<0.0001) versus no placebo patients (95% CI: 0.0%, 16.1%). Doptelet was generally well-tolerated. In pediatric patients with persistent or chronic immune thrombocytopenia, the most common adverse reactions (≥ 10%) were viral infection, nasopharyngitis, cough, pyrexia, and oropharyngeal pain.1 'Since its introduction in 2019, Doptelet has been a cornerstone therapy for chronic ITP in adults,' said Duane Barnes, President of Sobi North America. 'This approval not only reinforces our commitment to innovation but also allows us to expand the treatment experience for patients and their families by offering Doptelet in two formulations.' Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low numbers of platelets, leading to bruising and an increased risk of bleeding. It is estimated up to 100 people per million live with ITP. In children, ITP occurs in five out of 100,000 children per year and up to 25% of newly diagnosed pediatric ITP patients develop chronic ITP. Currently, no cure is available, and patients usually relapse after various treatments. Indications Doptelet is a thrombopoietin receptor agonist indicated for the treatment of: Thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. Thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment Thrombocytopenia in pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia who have had an insufficient response to a previous treatment Important Safety Information Doptelet is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease or immune thrombocytopenia. In patients with chronic liver disease, thromboembolic events (portal vein thrombosis) occurred in 0.4% (1/274) of patients receiving Doptelet. In adult patients with chronic immune thrombocytopenia, thromboembolic events (arterial or venous) occurred in 7% (9/128) of patients receiving Doptelet. Doptelet should not be administered to patients with chronic liver disease or immune thrombocytopenia in an attempt to normalize platelet counts. The most common adverse reactions in clinical trials were viral infection, nasopharyngitis, cough, pyrexia, and oropharyngeal pain. To report SUSPECTED ADVERSE REACTIONS, contact Sobi, Inc. at 1-866-773-5274 or FDA at 1-800-FDA-1088 or Please see the full Prescribing Information for Doptelet. * A durable response consisted of patients achieving a platelet count >=50,000/uL for six of the last eight weeks in the 12-week core phase of the AVA-PED-301 study. ** Efficacy was also evaluated by platelet response, defined as the proportion of subjects achieving at least two consecutive platelet assessments ≥50×10^9/L in the core phase in the absence of rescue medication. About Immune thrombocytopenia (ITP) Immune thrombocytopenia (ITP) is a rare, acquired autoimmune condition characterized by a low platelet count and an increased risk of bleeding, and represents a multi-faceted disease burden for children and adolescents. Bleeding can range from minor symptoms, such as bruising, to more severe findings such as intracranial hemorrhage. ITP can also have a significant impact on quality of life including severe fatigue and restrictions on physical activity due to risk of bleeding. About Doptelet® (avatrombopag) Doptelet is an orally administered thrombopoietin receptor agonist (TPO-RA) that mimics the biologic effects of TPO in stimulating the development and maturation of megakaryocytes, resulting in increased platelet count. It is approved by the US Food & Drug Administration (FDA) for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure and by the European Medicines Agency (EMA) for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure. In June 2019, Doptelet was approved by the FDA for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment and in 2021, Doptelet was approved by EMA for the treatment of primary chronic ITP in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). About Sobi North America As the North American affiliate of international biopharmaceutical company Sobi, the Sobi North America team is committed to Sobi's vision of being a leader in providing innovative treatments that transform lives for individuals with rare diseases. Our product portfolio includes multiple approved treatments focused on immunology, hematology and specialty care. With U.S. headquarters in the Boston area, Canadian headquarters in the Toronto area, and field sales, medical and market access representatives spanning North America, our growing team has a proven track record of commercial excellence. More information is available at or at About Sobi® Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media, click here. References 1. Doptelet Prescribing Information. Doptelet U.S. Product Information. Last updated: July 2025. Morrisville, NC: AkaRx, Inc. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Hamilton Spectator
4 days ago
- Hamilton Spectator
Toronto Zoo welcomes wood bison calf born from artificial insemination
If you're visiting the Toronto Zoo, you may catch a peek of the freshest face at the site's Canadian domain. The zoo welcomed a female wood bison calf on June 30, who was born using an innovative single artificial insemination technique. The calf hasn't been named yet but zookeepers have been calling her 'little baby,' media co-ordinator Amy Baptista told the Star. 'This new calf represents a significant milestone for our continued conservation efforts with this iconic North American species,' the zoo wrote in a release Tuesday. Zoologists said the calf is strong, alert, in good health, bonding well with its mother and growing fast, which are all important when raising a wild animal in human care. The zoo has been involved in wood bison conservation since 1977 and partnered with the University of Saskatchewan and Parks Canada in 2007. It is important the calf is female, since female bison become pregnant and give birth and a herd can be rebuilt more efficiently if the population is skewed toward females temporarily, the release said. 'We continue to be home to one of a few reproductive physiology labs in North America that participate in biobanking wildlife species,' the release reads. 'This is the process of freezing living cells such as sperm and embryos, for the purpose of preserving genetic diversity for the future. Once frozen, these living cells are then held in Canada's Wildlife Cryobank at your Toronto Zoo.' Wood bison could previously be found across the boreal forests of northwestern Canada and Alaska but changes to their habitat use have created small, disconnected herds in British Columbia, Alberta, the Northwest Territories and Yukon. The species' status has been downgraded from 'endangered' to 'threatened' since 1988 but diseases, such as tuberculosis and brucellosis, still threaten the wild population. In 2016, three wood bison were unexpectedly found dead by Toronto Zoo staff, including one just a year and a half old and applauded as the zoo's first second-generation artificially inseminated bison. With files from Sammy Hudes Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
